Action of kappa and Delta opioid agonists on premotor cardiac vagal neurons in the nucleus ambiguus.
Both enkephalin and dynorphin containing fibers are in close proximity to neurons in the nucleus ambiguus, including cardiac vagal neurons. Microinjection of Delta and kappa agonists into the nucleus ambiguus have been shown to evoke decreases in heart rate. Yet little is known about the mechanisms by which Delta and kappa opioid receptors alter the activity of cardiac vagal neurons. This study tests whether kappa and Delta opioid agonists can alter the activity of cardiac vagal neurons by modulating likely opioid targets including voltage gated calcium currents, and both glycinergic and GABA) neurotransmission to cardiac vagal neurons. Cardiac vagal neurons were identified in vitro by a fluorescent tracer and studied using patch clamp techniques. Neither the kappa agonist spiradoline or the Delta agonist [D-Pen(2), D-Pen(5)]enkephalin (DPDPE) modulated the voltage gated calcium currents in cardiac vagal neurons. DPDPE also did not alter either glycinergic or GABAergic synaptic neurotransmission. Spiradoline did not change GABAergic synaptic inputs, but did significantly inhibit glycinergic synaptic inputs to cardiac vagal neurons. At a concentration of 1 microM, spiradoline inhibited the amplitude of glycinergic events, and at a concentration of 5 microM, spiradoline inhibited both glycinergic amplitude and frequency. Spiradoline also inhibited both the amplitude and frequency of glycinergic miniature inhibitory post-synaptic currents, indicating kappa agonists likely act at both presynaptic and postsynaptic sites to inhibit glycinergic neurotransmission to cardiac vagal neurons.
Wang
X
X
Department of Pharmacology and Physiology, George Washington University, 2300 Eye Street Northwest, Washington, DC 20037, USA.
Dergacheva
O
O
Griffioen
K J S
KJ
Huang
Z-G
ZG
Evans
C
C
Gold
A
A
Bouairi
E
E
Mendelowitz
D
D
D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology; D020881:Enkephalin, D-Penicillamine (2,5)- / Q000494:pharmacology; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology; D005998:Glycine / Q000187:drug effects / Q000378:metabolism; D006321:Heart / Q000294:innervation*; D008526:Medulla Oblongata / Q000187:drug effects / Q000502:physiology*; D018408:Patch-Clamp Techniques; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018079:Receptors, GABA / Q000187:drug effects / Q000378:metabolism; D017465:Receptors, Opioid, delta / Q000819:agonists*; D017473:Receptors, Opioid, kappa / Q000819:agonists*; D014630:Vagus Nerve / Q000187:drug effects / Q000502:physiology*
D000701:Analgesics, Opioid; D000889:Anti-Arrhythmia Agents; D015220:Calcium Channels; D011759:Pyrrolidines; D018079:Receptors, GABA; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D020881:Enkephalin, D-Penicillamine (2,5)-; C051272:spiradoline; D005998:Glycine